Imaging in Stem Cell Transplant and Cell-based Therapy

85

47. Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High­dose che­
    motherapy plus autologous stem­cell transplantation as consolidation therapy in patients with
    relapsed multiple myeloma after previous autologous stem­cell transplantation (NCRI
    Myeloma X Relapse [Intensive trial]): a randomised, open­label, phase 3 trial. Lancet Oncol.
    2014;15(8):874–85.


48. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood
    and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood
    and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group
    Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with
    Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015;21(12):2039–51.


49. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assess­
    ment predicts survival and toxicities in elderly myeloma patients: an International Myeloma
    Working Group report. Blood. 2015;125(13):2068–74.


50. Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, et al. Trends in autolo­
    gous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and
    improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;
    50(2):209–15.


51. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and predni­
    sone plus thalidomide versus melphalan and prednisone alone or reduced­intensity autologous
    stem cell transplantation in elderly patients with multiple myeloma (IFM 99­06): a randomised
    trial. Lancet. 2007;370(9594):1209–18.


52. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell
    transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol.
    2001;114(3):600–7.


53. Morris CL, Siegel E, Barlogie B, Cottler­Fox M, Lin P, Fassas A, et al. Mobilization of CD34+
    cells in elderly patients (>/=70 years) with multiple myeloma: influence of age, prior therapy,
    platelet count and mobilization regimen. Br J Haematol. 2003;120(3):413–23.


54. Afifi S, Adel NG, Devlin S, Duck E, Vanak J, Landau H, et al. Upfront plerixafor plus G­CSF
    versus cyclophosphamide plus G­CSF for stem cell mobilization in multiple myeloma: effi­
    cacy and cost analysis study. Bone Marrow Transplant. 2016;51(4):546–52.


55. Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM, et al. A randomized
    phase II study of stem cell mobilization with cyclophosphamide  +  G­CSF or G­CSF alone
    after lenalidomide­based induction in multiple myeloma. Bone Marrow Transplant. 2016;
    51(3):372–6.


56. Abuabdou A, Rosenbaum ER, Usmani SZ, Barlogie B, Cottler­Fox M. Analysis of CD34+ cell
    collection using two mobilization regimens for newly diagnosed multiple myeloma patients
    reveals the separate impact of mobilization and collection variables. J  Clin Apher. 2014;
    29(5):251–5.


57. Papanikolaou X, Rosenbaum ER, Tyler LN, Sawyer J, Heuck CJ, Barlogie B, et  al.
    Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma:
    low platelet count predicts for poor collection and sole use of resulting graft enhances risk of
    myelodysplasia. Leukemia. 2014;28(4):888–93.


58. Uy GL, Rettig MP, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hema­
    topoietic stem cells. Expert Opin Biol Ther. 2008;8(11):1797–804.


59. van Rhee F, Giralt S, Barlogie B.  The future of autologous stem cell transplantation in
    myeloma. Blood. 2014;124(3):328–33.


60. Barlogie B, Anaissie E, van Rhee F, Pineda­Roman M, Zangari M, Shaughnessy J, et al. The
    Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin
    Haematol. 2007;20(4):761–81.


61. Koehne G, Giralt S. Allogeneic hematopoietic stem cell transplantation for multiple myeloma:
    curative but not the standard of care. Curr Opin Oncol. 2012;24(6):720–6.


62. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, et  al. Management of
    relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
    Leukemia 2015 Dec 29.

5 Stem Cell Transplantation for Multiple Myeloma